A Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX 101) in Children and Adolescents With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS1, or ALK Fusions

Trial Profile

A Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX 101) in Children and Adolescents With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS1, or ALK Fusions

Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Jun 2017

At a glance

  • Drugs Entrectinib (Primary)
  • Indications Nervous system neoplasms; Neuroblastoma; Solid tumours
  • Focus Adverse reactions
  • Acronyms STARTRK-NG
  • Sponsors Ignyta
  • Most Recent Events

    • 05 Apr 2017 Trial design presented at the 108th Annual Meeting of the American Association for Cancer Research.
    • 04 Jan 2017 Planned number of patients changed from 80 to 190.
    • 07 Apr 2016 According to an Ignyta media release, the data from this trial will be presented at the the 2016 Annual Meeting of the American Association for Cancer Research (AACR)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top